1
|
Cancer Genome Atlas Network. Comprehensive
molecular portraits of human breast tumours. Nature. 490:61–70.
2012. View Article : Google Scholar : PubMed/NCBI
|
2
|
Gao H, Chakraborty G, Lee-Lim AP, et al:
The BMP inhibitor Coco reactivates breast cancer cells at lung
metastatic sites. Cell. 150:764–779. 2012. View Article : Google Scholar : PubMed/NCBI
|
3
|
Cellurale C, Girnius N, Jiang F, et al:
Role of JNK in mammary gland development and breast cancer. Cancer
Res. 72:472–481. 2012. View Article : Google Scholar : PubMed/NCBI
|
4
|
Perrimon N, Pitsouli C and Shilo BZ:
Signaling mechanisms controlling cell fate and embryonic
patterning. Cold Spring Harb Perspect Biol. 4:a0059752012.
View Article : Google Scholar : PubMed/NCBI
|
5
|
Guo J and Wu G: The signaling and
functions of heterodimeric bone morphogenetic proteins. Cytokine
Growth Factor Rev. 23:61–67. 2012. View Article : Google Scholar : PubMed/NCBI
|
6
|
Singh A and Morris RJ: The Yin and Yang of
bone morphogenetic proteins in cancer. Cytokine Growth Factor Rev.
21:299–313. 2010. View Article : Google Scholar : PubMed/NCBI
|
7
|
Alarmo EL and Kallioniemi A: Bone
morphogenetic proteins in breast cancer: dual role in
tumourigenesis? Endocr Relat Cancer. 17:R123–R139. 2010. View Article : Google Scholar : PubMed/NCBI
|
8
|
Rhodes A, Jasani B, Barnes DM, et al:
Reliability of immunohistochemical demonstration of oestrogen
receptors in routine practice: interlaboratory variance in the
sensitivity of detection and evaluation of scoring systems. J Clin
Pathol. 53:125–130. 2000. View Article : Google Scholar
|
9
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
|
10
|
Deng S, Zhou H, Xiong R, et al:
Over-expression of genes and proteins of ubiquitin specific
peptidases (USPs) and proteasome subunits (PSs) in breast cancer
tissue observed by the methods of RFDD-PCR and proteomics. Breast
Cancer Res Treat. 104:21–30. 2007. View Article : Google Scholar : PubMed/NCBI
|
11
|
Zhou HY, Mei Y, Lu YG, et al: Application
of restriction fragment differential display-polymerase chain
reaction in study on differential expression profiles of human
diseases. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 22:294–297.
2005.
|
12
|
Piccirillo SG and Vescovi AL: Bone
morphogenetic proteins regulate tumorigenicity in human
glioblastoma stem cells. Ernst Schering Found Symp Proc. 5:59–81.
2006.PubMed/NCBI
|
13
|
Bunyaratavej P, Hullinger TG and Somerman
MJ: Bone morphogenetic proteins secreted by breast cancer cells
upregulate bone sialoprotein expression in preosteoblast cells. Exp
Cell Res. 260:324–333. 2000. View Article : Google Scholar : PubMed/NCBI
|
14
|
Shepherd TG, Thériault BL and Nachtigal
MW: Autocrine BMP4 signalling regulates ID3 proto-oncogene
expression in human ovarian cancer cells. Gene. 414:95–105. 2008.
View Article : Google Scholar : PubMed/NCBI
|
15
|
Barekati Z, Radpour R, Lu Q, et al:
Methylation signature of lymph node metastases in breast cancer
patients. BMC Cancer. 12:2442012. View Article : Google Scholar : PubMed/NCBI
|
16
|
Zhang M, Wang Q, Yuan W, et al: Epigenetic
regulation of bone morphogenetic protein-6 gene expression in
breast cancer cells. J Steroid Biochem Mol Biol. 105:91–97. 2007.
View Article : Google Scholar : PubMed/NCBI
|
17
|
Seckinger A, Meissner T, Moreaux J,
Goldschmidt H, Fuhler GM, Benner A, et al: Bone morphogenic protein
6: a member of a novel class of prognostic factors expressed by
normal and malignant plasma cells inhibiting proliferation and
angiogenesis. Oncogene. 28:3866–3879. 2009. View Article : Google Scholar
|
18
|
Takahashi M, Otsuka F, Miyoshi T, et al:
Bone morphogenetic protein 6 (BMP6) and BMP7 inhibit
estrogen-induced proliferation of breast cancer cells by
suppressing p38 mitogen-activated protein kinase activation. J
Endocrinol. 199:445–455. 2008. View Article : Google Scholar
|
19
|
Haudenschild DR, Palmer SM, Moseley TA,
You Z and Reddi AH: Bone morphogenetic protein (BMP)-6 signaling
and BMP antagonist noggin in prostate cancer. Cancer Res.
64:8276–8284. 2004. View Article : Google Scholar : PubMed/NCBI
|
20
|
Wach S, Schirmacher P, Protschka M and
Blessing M: Overexpression of bone morphogenetic protein-6 (BMP-6)
in murine epidermis suppresses skin tumor formation by induction of
apoptosis and downregulation of fos/jun family members. Oncogene.
20:7761–7769. 2001. View Article : Google Scholar : PubMed/NCBI
|
21
|
Coley HM: Mechanisms and consequences of
chemotherapy resistance in breast cancer. Eur J Cancer. (Suppl 7):
3–7. 2009. View Article : Google Scholar
|
22
|
Drasin DJ, Robin TP and Ford HL: Breast
cancer epithelial-to-mesenchymal transition: examining the
functional consequences of plasticity. Breast Cancer Res.
13:2262011. View
Article : Google Scholar : PubMed/NCBI
|
23
|
Chen GQ, Zhao ZW, Zhou HY, Liu YJ and Yang
HJ: Systematic analysis of microRNA involved in resistance of the
MCF-7 human breast cancer cell to doxorubicin. Med Oncol.
27:406–415. 2010. View Article : Google Scholar : PubMed/NCBI
|
24
|
Yang S, Du J, Wang Z, et al: Dual
mechanism of deltaEF1 expression regulated by bone morphogenetic
protein-6 in breast cancer. Int J Biochem Cell Biol. 41:853–861.
2009. View Article : Google Scholar : PubMed/NCBI
|
25
|
Yang S, Du J, Wang Z, et al: BMP-6
promotes E-cadherin expression through repressing deltaEF1 in
breast cancer cells. BMC Cancer. 7:2112007. View Article : Google Scholar : PubMed/NCBI
|
26
|
Foroni C, Broggini M, Generali D and Damia
G: Epithelial-mesenchymal transition and breast cancer: role,
molecular mechanisms and clinical impact. Cancer Treat Rev.
38:689–697. 2012. View Article : Google Scholar : PubMed/NCBI
|
27
|
Zhang YE: Non-Smad pathways in TGF-beta
signaling. Cell Res. 19:128–139. 2009. View Article : Google Scholar : PubMed/NCBI
|
28
|
Li B: Bone morphogenetic protein-Smad
pathway as drug targets for osteoporosis and cancer therapy. Endocr
Metab Immune Disord Drug Targets. 8:208–219. 2008. View Article : Google Scholar : PubMed/NCBI
|
29
|
Karam M, Legay C, Auclair C and Ricort JM:
Protein kinase D1 stimulates proliferation and enhances
tumorigenesis of MCF-7 human breast cancer cells through a
MEK/ERK-dependent signaling pathway. Exp Cell Res. 318:558–569.
2012. View Article : Google Scholar
|
30
|
Shen H, Xu W, Luo W, et al: Upregulation
of mdr1 gene is related to activation of the MAPK/ERK signal
transduction pathway and YB-1 nuclear translocation in B-cell
lymphoma. Exp Hematol. 39:558–569. 2011. View Article : Google Scholar : PubMed/NCBI
|
31
|
Guan J, Chen XP, Zhu H, Luo SF, Cao B and
Ding L: Involvement of extracellular signal-regulated
kinase/mitogen-activated protein kinase pathway in multidrug
resistance induced by HBx in hepatoma cell line. World J
Gastroenterol. 10:3522–3527. 2004.PubMed/NCBI
|